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OBJECTIVES Our objective was to evaluate the short-term safety and efficacy of cardiac resynchronization
therapy (CRT) in children.
BACKGROUND Cardiac resynchronization therapy has been beneficial for adult patients with poor left
ventricular function and intraventricular conduction delay. The efficacy of this therapy in the
young and in those with congenital heart disease (CHD) has not yet been established.
METHODS This is a multi-center, retrospective evaluation of CRT in 103 patients from 22 institutions.
RESULTS Median age at time of implantation was 12.8 years (3 months to 55.4 years). Median duration
of follow-up was four months (22 days to 1 year). The diagnosis was CHD in 73 patients
(71%), cardiomyopathy in 16 (16%), and congenital complete atrioventricular block in 14
(13%). The QRS duration before pacing was 166.1  33.3 ms, which decreased after CRT
by 37.7  30.7 ms (p  0.01). Pre-CRT systemic ventricular ejection fraction (EF) was 26.2 
11.6%. The EF increased by 12.8  12.7 EF units with a mean EF after CRT of 39.9 
14.8% (p  0.05). Of 18 patients who underwent CRT while listed for heart transplantation,
3 improved sufficiently to allow removal from the transplant waiting list, 5 underwent
transplant, 2 died, and 8 others are currently awaiting transplant.
CONCLUSIONS Cardiac resynchronization therapy appears to offer benefit in pediatric and CHD patients
who differ substantially from the adult populations in whom this therapy has been most
thoroughly evaluated to date. Further studies looking at the long-term benefit of this therapy
in this population are needed. (J Am Coll Cardiol 2005;46:2277–83) © 2005 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.05.096American College of Cardiology Foundation
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iardiac resynchronization therapy (CRT) using biventricu-
ar pacing has been shown to be a beneficial therapy in
dults with left ventricular dysfunction and intraventricular
onduction delay (1–7). In patients with left ventricular
ailure and left bundle-branch block, CRT has produced
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Resynchronization Therapy in Pediatrics December 20, 2005:2277–83ongenital heart disease (CHD) has not been established,
nd comprises the subject of this report.
Several studies of CRT in patients after surgery for
ongenital heart defects have shown that CRT improves
emodynamics (8,9). Chronic biventricular CRT in this
opulation is the subject of case reports and several small
tudies (8–15). Thus, it is not known whether the pediatric
xperience will resemble that seen with adults, as the patient
ubstrate differs markedly from adult patients. Therefore, the
bjective of this study was to review a multi-center experience
ith CRT in pediatric patients and those with CHD.
ETHODS
his study is a retrospective investigation that was initiated
hrough the Pediatric Electrophysiology Society. Twenty-
wo centers in the U.S., Canada, and Europe participated
see online Appendix). Members of the Society were asked
o report on the indications, outcomes, and complications
or all patients who received biventricular CRT and were
nder 21 years of age, or who had CHD regardless of age.
nstitutional review board approval to report this data was
btained from each site. Data collected included underlying
eart disease, indication for implant, measurements of
linical status (New York Heart Association [NYHA]
unctional class or Ross status as reported by site physician)
nd cardiac function (using echocardiogram or radionuclide
can), as well as clinical outcome (16).
Values are expressed as either median (range) or mean
 SD) depending on the distribution of the data. Cate-
orical variables were evaluated by chi-square analysis.
ontinuous variables were evaluated by analysis of variance
nd two-tailed t tests. Relationships between continuous
ariables were explored using univariate linear regression.
ESULTS
atients. Devices capable of biventricular CRT were
mplanted in 103 patients 21 years of age or with
HD. The median age at CRT implantation was 12.8
ears (3 months to 55.4 years) as shown in Figure 1.
here were 17 patients over 21 years of age, all of whom
ad CHD. There were 11 patients less than one year old.
verall, 73 (71%) patients had CHD, 16 (16%) had
ardiomyopathy, and 14 (13%) had congenital complete
trioventricular block. Thirty-nine patients were reported
o be NYHA functional class 3 or 4 before CRT; 15
Abbreviations and Acronyms
CHD  congenital heart disease
CRT  cardiac resynchronization therapy
EF  ejection fraction
ICD  implantable cardioverter-defibrillator
NYHA  New York Heart Associationatients were reported to be NYHA class 1.
E
dCongenital heart disease diagnoses included: left-sided
bstructive lesions (n  15); l-transposition of the great
rteries with systemic right ventricular failure (n  12);
etralogy of Fallot or variant lesion (n 11); atrioventricular
anal defect (n  10); d-transposition of great arteries (n 
2); and other (n  13). Single ventricle physiology was
resent in seven patients. Pacemakers had previously been
mplanted in 27 patients because of surgical atrioventricular
lock. These patients were paced a median of 8.6 years (5
onths to 35.5 years) before upgrade to CRT with ventric-
lar pacing in 11 patients and dual-chamber pacing in 14
atients.
There were 16 patients with cardiomyopathy, including
0 with dilated cardiomyopathy; 4 with hypertrophic car-
iomyopathy; 1 with a metabolic myopathy; and 1 with
uchenne’s muscular dystrophy. Pacemakers had previously
een implanted in six of these patients for a median of 4.3
ears (0.8 months to 5.1 years) before upgrade to CRT.
Fourteen patients had congenital complete atrioventric-
lar block with a median age of 12.5 years (3 months to 24.3
ears). Ten were previously paced with dual-chamber (atrio-
entricular) systems, and three were paced only with ven-
ricular leads before CRT. One patient received CRT as
rimary therapy. These patients were paced a median of 5.3
ears (3 months to 17.7 years) before upgrade to CRT.
Of the total population, 96 were taking at least one heart
ailure medication, and 6 patients were dependent on
ositive inotropic agents. Table 1 lists details of the medi-
ations taken and support required before placement of a
igure 1. Histogram of age distribution of patients who received cardiac
esynchronization therapy therapy.
able 1. Patient Therapies Before and After CRT Pacemaker
lacement
Therapy Pre-CRT Post-CRT
igoxin 63 63
iuretics 59 56
CE inhibitors 66 70
eta-blockers 31 38
ositive inotropic agents 6 2
CMO/LVAD 0 2
one 5 5
nknown 9 9
CE  angiotensin-converting enzyme; CRT  cardiac resynchronization therapy;
CMO  extracorporeal membrane oxygenation; LVAD  left ventricular assist
evice.
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December 20, 2005:2277–83 Resynchronization Therapy in Pediatricsiventricular system. There were 18 patients who were listed
or heart transplantation.
ystems. In 45 patients, a transvenous CRT placement was
erformed; in 48, the system was epicardial; and in 10
atients a mixed system was used (Fig. 2). Mixed systems
ere used exclusively in CHD patients. Patients receiving
picardial systems were younger than those who received
igure 2. (A) Chest film of a patient with an epicardial biventricular pacing
ystem. (B) Chest film of a patient who required a mixed biventricular
acing system. The left ventricular lead was placed epicardially and
unneled to the generator, whereas the implantable cardioverter-
efibrillator lead and atrial lead were placed transvenously.
able 2. Type of CRT System and Adverse Events by Type of H
Type of Heart Disease
Acute Adverse
Events
(%)
Late Adver
Events
(%)
ongenital heart disease 13 (18%) 8 (11%)
ardiomyopathy 5 (31%) 1 (6%)
eart block 2 (14%) 1 (7%)
Value NS NSRT  cardiac resynchronization therapy; ICD  implantable cardioverter-defibrillator.ransvenous systems (4.6 vs. 16.9 years, p  0.05). Implant-
ble cardioverter-defibrillator (ICD) capability was included
n 20 devices; of these, 6 were in patients with cardiomy-
pathy, and 14 were in patients with CHD (Table 2). The
edian age at implant for a CRT/ICD system was 17.2
ears (9 to 55.4 years), which was significantly older when
ompared with the rest of the group: 11.5 years (4 months
o 51.4 years), (p  0.05). However, ejection fraction (EF)
as similar between the groups (26.6  11.7% for the CRT
roup vs. 23.7  10.8% for the CRT/ICD group).
linical status. Follow-up data were obtained 4.8  4
onths after initiation of CRT. In the 94 patients with data
vailable, the mean QRS duration before CRT was 166 
3 ms, which decreased to 126  24 ms after CRT (p 
.01). Ejection fraction before and after CRT was available
n 89 patients (74 by echocardiography and 14 by radionu-
lide scan). The mean EF of the systemic ventricle before
RT was 26.2  12%, which increased by 13  13 EF
nits (p  0.05). The EF after CRT was 40  15%.
ifty-six patients met adult criteria for CRT with an EF
35% and a QRS duration of 120 ms. No relationship
ould be found between baseline EF or QRS duration and
F improvement.
Table 1 shows medical support required after biventricu-
ar pacemaker placement. Of the six patients on intravenous
ositive inotropic agents before CRT placement, five were
eaned from this support after implantation. Of 18 patients
isted for transplantation at the time of CRT, 3 improved
nd were removed from active listing, 5 underwent trans-
lant, 2 died, and 8 are currently awaiting transplant.
ffect of CRT by type of heart disease. Table 3 shows the
ffect of CRT when separated into differing types of heart
isease. No significant differences could be seen when
omparing EF improvement or QRS improvement by type
f heart disease. No difference in complication rate was seen
n any of the groups.
pgrade of pacemaker to CRT. Forty-six patients had
revious pacemaker systems in place before upgrade to
RT. These systems were in place a median of 6.0 years (24
ays to 35.5 years) before upgrade to CRT. These patients
ad a significant improvement in EF with CRT therapy
14.5  11.4 EF units) (p  0.05). They also had a
ignificant decrease in QRS duration of 46.2  36.1 ms
p  0.05). No significant differences in age of patients,
aseline EF, or change in EF were seen comparing those
ho had prior pacemaker therapy with those who did not.
Disease
Transvenous
System
(%)
Epicardial/Mixed
System
(%/%)
ICD
Capability
(%)
26 (36%) 37/10 (51%/14%) 14 (19%)
12 (75%) 4/0 (25%) 6 (37%)
7 (50%) 7/0 (50%) 0 (0%)
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Resynchronization Therapy in Pediatrics December 20, 2005:2277–83owever, the patients with prior pacemakers had a signif-
cantly longer QRS duration than those who did not (178
1 ms vs. 160  30.1 ms, p  0.05), with greater
mprovement in QRS duration (46.2  36.1 ms vs. 31.1 
2.9 ms, p  0.05).
niventricular hearts. Seven patients had single ventricle
hysiology. Three patients had completed a total cavopul-
onary connection, whereas the other four had bidirec-
ional Glenn shunts. These patients all received epicardial
ead systems. Ventricular leads were placed as far apart as
ossible. Median age at implant was 3.1 years (5 months to
3.7 years). Ejection fraction was measured by radionuclide
can in four of the seven, whereas function was subjectively
escribed in the remaining three. These patients had no
ignificant increase in EF (7.3  5.7 EF units) (p  0.08)
nd no change in qualitative echo measurement, but did
ave a significant decrease in QRS duration of 44.8  26.2
s (p  0.05). There was clinical improvement in two of
he seven.
ystemic right ventricles. There were 17 patients with
ystemic right ventricles who received CRT therapy. Diag-
oses included l-transposition of the great arteries in 13 and
-transposition of great arteries status after Senning or
ustard procedure in four. Median age at implant was 12.7
ears (4.9 to 50.0 years). Ejection fraction data were
vailable in 12 systemic right ventricle patients. These
atients had a significant increase in systemic EF (13.3 
1.3 EF units) and a significant decrease in QRS duration
38.2  29.4 ms) (p  0.05). Thirteen of these patients had
linical improvement.
on-responders. Non-responders were defined as those
ho had either no change in their EF with CRT, or a
ecrease in their EF. There were 11 non-responders. Table
compares baseline characteristics of responders with non-
esponders. Thirteen of these patients were receiving some
nti-congestive medical therapy before upgrade (8 patients
ere receiving an angiotensin-converting enzyme inhibitor,
diuretics, and 3 beta-blockers). There was a significant
Table 3. Effect of CRT Pacing by Type of He
Type of Disease n Age (yrs)
Congenital heart disease 73 12.2 (0.5–55.4)
Cardiomyopathy 16 15.8 (0.3–19.6)
Heart block 14 12.5 (0.3–24.3)
p Value NS
CRT  cardiac resynchronization therapy; EF  ejection fr
Table 4. Characteristics of CRT Responders V
Responder
Age (yrs) 11.9 (0
Baseline EF (%) 24.3 
Baseline QRS (ms) 166.5 
Change in QRS (ms) 36.8 
% with CHD 71
Baseline NYHA functional class 3/4 38CHD congenital heart disease; CRT cardiac resynchronization
Association.ifference in the EF before CRT, with the responders
aving a lower EF of 24.3  11.0% versus an EF of 32.0 
4.2% in the non-responders (p  0.04). QRS duration
ecreased an average of 33.4  18.3 ms in non-responders
p  0.05), which was not different than the responders
36.8  24.7 ms).
dverse events. Two patients had significant clinical de-
erioration closely following placement of biventricular
acemakers. One patient who was on oral anti-congestive
gents required initiation of intravenous positive inotropic
upport after pacemaker placement, and one patient re-
uired extracorporeal membrane oxygenation after pace-
aker placement. This patient subsequently died.
In the entire cohort, there were 23 acute adverse events
eported in 20 patients, which are summarized in Table 5.
hese included three deaths. The deaths occurred four days
nd two weeks (two patients) after the procedure. There
ere five reported coronary sinus lead issues, including one
nstance where the coronary sinus could not be entered with
he pacer lead secondary to small size (the patient was 20
ears of age). There were three arrhythmic episodes, and
hree cases of inadequate defibrillation threshold in pace-
akers with ICD capability (all three in transvenous sys-
ems). There were two device pocket hematomas, and one
ach of the following: pocket infection, cerebrovascular
ccident, bleeding, and perforation of the myocardium
equiring surgical intervention.
Delayed adverse events occurred in 10 patients. These
ncluded two additional deaths. There were also three
eports of coronary sinus lead dislodgement, one lead
daptor malfunction, one pacer site infection, and three
rrhythmic episodes.
Thus, there was an overall adverse event rate of 29%.
verall mortality was 5%. Coronary sinus lead issues, which
ccounted for 23% of the reported complications, and were
ound in 18% of all transvenous pacemakers placed, were the
ingle most common major complication.
isease
Improvement (EF units) QRS Shortening (ms)
11.9  12.9% 39.1  31.9
12.3  13.6% 31.9  37.9
16.1  12.9% 36.8  13.0
NS NS
.
s Non-Responders
78) Non-Responders (n  11) p Value
.4) 14.8 (3.1–18.4) NS
32.0  14.2 0.04
172.9  21.3 NS
33.4  18.3 NS
73% NS
31% NSart D
EFersu
s (n 
.4–55
11.0
33.2
24.7
%
%therapy; EF ejection fraction; NYHANew York Heart
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December 20, 2005:2277–83 Resynchronization Therapy in PediatricsNo differences in complication rates could be seen when
omparing transvenous placement versus epicardial or
ixed placement of devices: acute adverse events were seen
n 10 of 45 (22%) transvenous systems and 10 of 58 (17%)
picardial/mixed systems, whereas late events were found in
(15%) transvenous systems and 3 (5%) epicardial/mixed
ystems (p  NS for all). Arrhythmic episodes were found
n four epicardial systems and two transvenous systems (p
S). When comparing ICD systems versus pacing systems,
here were also no significant differences in complication
ates, with an acute adverse event rate of 37% versus 16% (p
.08) and a late adverse event rate of 11% versus 10% (p 
S). However, the small numbers of patients for compar-
son limit the power of this observation.
eaths. EARLY DEATHS. One patient died suddenly four
ays after CRT implantation. This patient had aortic
tenosis requiring an aortic valve replacement. He developed
rogressive left ventricular dysfunction and had an EF of
7% at the time of CRT therapy. The patient also had
yncope but no documented arrhythmia. Four days after
mplantation of a biventricular pacemaker/ICD, he had a
entricular fibrillation cardiac arrest while climbing stairs.
nterrogation of his device revealed appropriate therapy and
onversion to normal sinus rhythm. He subsequently devel-
ped electrical storm that did not respond to any antiar-
hythmics. He was emergently placed on extracorporeal
embrane oxygenation support that was unsuccessful.
Two patients died within 30 days after their procedure.
either patient had documented arrhythmia before CRT
herapy. The first was a seven-year-old, status post–atrial
eptal defect closure, with surgical heart block in the first
ear of life. At age 7, he developed dilated cardiomyopathy
EF 23%) and his dual-chamber pacemaker was upgraded
o a biventricular system. Two weeks after implant, he
resented to an emergency room in a wide complex tachy-
ardia after a sudden collapse. After multiple defibrillation
able 5. Acute and Late Adverse Events
Acute Late
eaths 3 2
VA 1
ite infection 1 1
ite hematoma 3
nadequate DFTs 3
S issues 5 3
Dislodgement 3 2
Difficulty placing lead 1
Diaphragm capture 1 1
lood loss 1
trial arrhythmia (flutter or fibrillation) 2
entricular arrhythmia (including VT/VF) 3 2
A or RV lead issues 1 2
neumothorax 1
ardiac perforation 1
S  coronary sinus; CVA  cerebrovascular accident; DFTs  defibrillation
hreshold; RA  right atrial; RV  right ventricular; VF  ventricular fibrillation;
T  ventricular tachycardia.ttempts, he was unable to be resuscitated. The second tatient was a 39-year-old with left transposition of the great
rteries, ventricular septal defect with complete atrioventric-
lar block. He underwent biventricular pacemaker upgrade
t the time of his double switch procedure. Unfortunately,
e was not able to be weaned from cardiopulmonary bypass
nd was thus placed directly onto extracorporeal membrane
xygenation support. He died of pump failure two weeks
fter implant.
ATE DEATHS. There were two late deaths. Neither of these
atients had prior documented arrhythmias. One of these
ccurred in a patient who had a ventricular septal defect
epaired in infancy and developed surgical heart block
equiring a VVIR pacemaker. At age 10, he was noted to
ave a severe cardiomyopathy with a shortening fraction of
0% despite optimal anticongestive therapy. He was up-
raded to a biventricular pacemaker. He died suddenly eight
eeks later. Interrogation of his device revealed runs of
entricular tachycardia.
The second late death occurred in a 35-year-old patient
tatus post repair of atrioventricular septal defect who had
rogressive left ventricular dysfunction and required a ven-
ricular assist device several months after CRT therapy was
nstituted. This patient died of incessant ventricular ar-
hythmias and poor cardiac output while on the ventricular
ssist device.
tudy limitations. This study, while the largest experience
n the pediatric population for this new therapy, is retro-
pective in nature, and thus has some limitations inherent to
ts design. The NYHA/Ross classification is highly subjec-
ive, especially when assigned in a retrospective manner.
he varied cardiac anatomy in this study required multiple
echniques for measuring EF, which can be difficult to
ompare.
ISCUSSION
ardiac resynchronization therapy has been shown to be a
owerful tool in the adult patient with left-sided heart
ailure. This therapy has been well tested in the adult patient
ith intraventricular conduction delay and ventricular dys-
unction (1–3,5,7,17). However, there have been no equiv-
lent studies of CRT performed in pediatric patients. Of
ote, there are comparatively few pediatric patients who fit
he classic criteria employed for adults. Indeed, in this study,
nly 16% of patients had a biventricular pacing system
mplanted for cardiomyopathy, whereas 54% of patients
ulfilled EF and QRS criteria for CRT in adults. The great
ajority of patients had poor systolic function and CHD,
ncluding patients with single ventricle physiology. Thus,
ndications for CRT are markedly different, with 71% of
atients having CHD. The literature provides little guid-
nce to predict the response to CRT of patients such as
hese. As such patients commonly develop congestive heart
ailure in early adulthood, and often become transplant
andidates, a careful consideration of the effects of CRT in
his unique group is essential.
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Resynchronization Therapy in Pediatrics December 20, 2005:2277–83Interestingly, though the indications for CRT were quite
eterogeneous, patients overall showed an improvement in
F as well as clinical status. Furthermore, five of the six
ritically ill patients dependent upon positive inotropic
upport were weaned to oral therapy with the aid of
iventricular pacing. No differences in response could be
ound based on the indication for implantation.
There were 11 patients whose EFs did not improve with
RT. These patients had a significantly better EF at
aseline than the responders, raising the question of
hether these patients were “too well” to benefit from CRT.
nterestingly, three of these patients had improved clinical
tatus despite having no change in their EF. Yu et al.
erformed a multivariate analysis of adult heart failure
atients with CRT therapy and found that systolic dyssyn-
hrony measured with tissue Doppler imaging was the only
redictor of left ventricular remodeling (18). It is clear that
RS duration alone cannot determine which patients will
mprove, and that further work looking at the mechanical–
lectrical interaction is necessary in this population.
Almost one-half the patients who had CRT instituted in
he present study had a previous pacemaker system in place.
s might be expected, these patients’ QRS durations were
omewhat more prolonged, and shortened more than pa-
ients who were not paced. These patients had the same
mprovement in EF and clinical status as did the patients
ho had intrinsic conduction delay. Thus it does not appear
hat the benefit of CRT in pediatric patients is dependent
n intrinsic conduction delay per se. Further studies are
eeded to assess whether this therapy should be considered
s a primary therapy when pacing is required.
Another group unique to this series is that of univen-
ricular hearts. There were seven patients in whom multi-
ite, univentricular pacing was attempted. These patients
id not have a clinically significant change in EF with the
nstitution of multi-site pacing. Although the number of
atients in this group is quite small, a few preliminary
onclusions can be made. The effect of pacing on ventricular
unction was quite marginal in this group, all of whom
equired epicardial pacing. Therefore, the risk-benefit ratio
n this group is less clearly in favor of pacing. This finding
eems to contradict acute data reported by Zimmerman et
l. (19) which found a 14% increase in cardiac output in
ingle ventricle patients with multi-site pacing in the post-
perative period.
Cardiac resynchronization therapy was instituted in 17
atients with systemic right ventricles. Janousek et al. (15)
rst reported on the use of CRT for systemic right ventric-
lar failure in this subset of patients. We found that these
atients had improvement in both systemic EF and clinical
tatus with the institution of CRT.
We found marked variability in implantation technique,
ith half of the devices implanted using an epicardial or
ixed approach, which is uncommon in the adult experi-nce. This stresses the need for further development of newools and techniques for accessing the posterior epicardial
urface in the pediatric and CHD populations.
The high adverse event rate of 29% appears comparable
o the experience with adults (20). Coronary sinus lead
ssues were found in 18% of patients who received trans-
enous systems, which is somewhat higher than what was
ound in the Multicenter Insync Randomized Clinical
valuation (MIRACLE) trial (12% for dissection, perfora-
ion, or lead dislodgement) (17). This may be related to
natomic issues found in the pediatric patient or patient
ith CHD. As this is a relatively new technique, operator
xperience may also have a role in this issue.
There were five deaths reported in this series, comparable
o the 5% mortality reported in the MIRACLE trial (17).
hree of the five deaths were related to ventricular arrhyth-
ias, whereas two appeared to be pump failure. The
omparison of Medical Therapy Pacing and Defibrillation
n Heart Failure (COMPANION) trial showed a signifi-
ant decrease (36%) in mortality with CRT/ICD therapy
1). Several other studies have suggested that CRT may
ctually suppress the incidence of ventricular arrhythmias
21,22). However, there have been other investigators who
ropose that multi-site pacing may actually be proarrhyth-
ic (23). We found several patients (including three of the
ve patients who died) who had new-onset ventricular
rrhythmias after CRT therapy. Conversely, only 19% of
ur patients underwent CRT/ICD therapy, a much smaller
ercentage than that seen in recent adult trials. Whether the
ew-onset ventricular arrhythmia seen in this population
epresents true proarrhythmia or is simply a sequela of a
everely ill population will need to be further investigated
nd may alter present indications for ICD placement.
Thus, while the indications for biventricular pacer place-
ent differ markedly from the pediatric population to the
dult population, there are pronounced hemodynamic ben-
fits in both groups, as well as favorable electrical and
echanical changes in the heart. Further studies into the
echanism of this improvement in this vastly different
ubstrate are needed, as are longer-term clinical studies.
eprint requests and correspondence: Dr. Anne M. Dubin, 750
elch Road, Suite 305, Palo Alto, California 94304. E-mail:
mdubin@stanford.edu.
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